Keep yourself up to date
‘Decoy’ Protein Offers New Treatment Approach For Covid-19 – (Forbes.com)
This article is an excellent write up via William Haseltine of Forbes regarding the ACE2 research that scientists at Cyrus have been a part of.
Keep yourself up to date
This article is an excellent write up via William Haseltine of Forbes regarding the ACE2 research that scientists at Cyrus have been a part of.
Improving the discovery of novel drugs with artificial intelligence.
(Nature.com) – Vaccine hesitancy and emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) escaping vaccine-induced immune responses highlight the urgency for new COVID-19 therapeutics […]
SEATTLE, WA – (BUSINESS WIRE) – Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary platform for biologics discovery that combines software, AI and large-scale parallel protein screening, today announced that its pre-clinical stage COVID therapeutic lead molecule, ACE2.v2.4 strongly binds the spike protein of SARS-CoV-2 variant of concern (VOC) omicron. ACE2.v2.4 was engineered […]
SEATTLE, WA December 6, 2021 — Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary software platform for biologics discovery, today announced the closing of a $18M Series B financing and acquisition of Orthogonal Biologics, a deep mutational scanning protein engineering spin-out from the University of Illinois at Urbana Champaign. The financing includes investments […]